Sangamo BioSciences | SGMO - Net Income


Sangamo BioSciences reported $-36.13M in Net Income for its fiscal quarter ending in June of 2024.





Net Income Change Date
Alaunos Therapeutics USD -1.01M 153K Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
Amgen USD 1.82B 486M Mar/2026
Bayer EUR 2.76B 6.52B Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Cipla INR 5.55B 1.21B Mar/2026
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD -7.67M 64.51M Mar/2026
CSL USD 401M 96.5M Dec/2025
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Grifols EUR 114.37M 34.03M Dec/2025
Ionis Pharmaceuticals USD -93M 136M Mar/2026
J&J USD 5.24B 119M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Novartis USD 3.16B 747M Mar/2026
Omeros USD -32.23M 23.81M Sep/2024
Pfizer USD 2.69B 4.34B Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 1.61B 2.42B Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Tectonic Therapeutic USD -25.24M 6.02M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026